Health

We continue to work in collaboration with our county health partners and, in the event of an identified COVID-19 outbreak, we will conduct contact tracing and inform the school community of additional mitigation strategies, which may include mask-wearing and PCR or rapid testing on-site or at home. We will monitor the number of cases and adjust our strategy to ensure the health and safety of students, staff and communities.

Montgomery County Public Schools


MCPS

Ten age-appropriate student focus groups at all three levels in February and March.

A series of youth-police dialogues with MCPS and police representatives in each of the 10 police districts in Montgomery County.


MoCo Government

According to a report by the Washington Post, Montgomery County Council At-Large candidate Brandy Brooks said Monday that she has no intention of withdrawing from the upcoming election.  Brooks paused her campaign on April 13 after allegations came out that she sexually harassed a former campaign staff member.

I believe that accountability must be based in honest fact-finding with the goal of seeking the truth. For decisions about my character and leadership to be made with such prejudice prior to any process is the very opposite of justice, by any definition. I am very proud of what our team of supporters, volunteers, and advisors have been able to accomplish over the last 15 months. While I am taking a momentary break, the campaign is not ending. I remain committed to the vision we’ve been building for Montgomery County.


MCPS

On Tuesday, the Montgomery County Council will receive a briefing on the memorandum of understanding between the Montgomery County Police Department and MCPS regarding the Community Engagement Officer Program. MCPS Superintendent Dr. Monifa McKnight, BOE President Brenda Wolff, and Montgomery County Police Chief Marcus Jones will be among those in attendance.


Gaithersburg

GAITHERSBURG, Md., April 22, 2022/PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, has initiated administration of the first booster doses of NVX-CoV2373, the company’s protein-based COVID-19 vaccine, in the pediatric expansion of the PREVENT-19 pivotal Phase 3 clinical trial. The study will evaluate the safety and immunogenicity of a third dose of NVX-CoV2373 among trial participants aged 12 through 17.

“We see the ongoing need for alternative vaccine options because we are continuing to monitor spikes in COVID-19,” said Gregory M. Glenn, M.D., President, Research and Development, Novavax. “The expansion of our PREVENT-19 booster trial into the pediatric population reinforces our commitment to seek to make our vaccine available to a broader population.”


View More Stories